Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A11QVV0
Thu, 25.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed
Early evidence of clinical activity observed in Cohort 8, highlighted by a very good partial response observed in one pa [ … ]
Thu, 25.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Milestone payment of USD 70 million from royalty financing agreement with HealthCare Royalty delayed as payment condition has not yet been met
Clinical Phase I/IIa trial with HDP-101 in Multiple Myelom [ … ]
Thu, 25.09.2025
Heidelberg Pharma AG
Ad hoc announcement
Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014
Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Milestone payment of USD 70 million from royalty financing agreement with HealthCare Royalty delayed as payment co [ … ]
Thu, 04.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Ladenburg, Germany, 4 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Thu, 28.08.2025
Heidelberg Pharma AG
Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
FDA has requested additional data relating to the Chemistry, Manufacturing, and Controls (CMC) package
Expected payment of USD 70 million from HealthCare Royalty to Heidelberg Pharma will be delayed
Current cash reach until Q1 2026
Ladenbu [ … ]
Thu, 10.07.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data
Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started
First patient in clinical study dosed with the second ATAC c [ … ]
Tue, 27.05.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Ladenburg, Germany, 27 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the first patient has been [ … ]
Thu, 15.05.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
All agenda items approved by a large majority
2025 Annual General Meeting elects Dr Karl Benedikt Biesinger and Dr Klaus Schollmeier as new members of the Supervisory Board
Supervisory Board elects Dr Karl Benedikt Biesin [ … ]
Wed, 14.05.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
HDP-101 demonstrated complete response in one female patient from cohort 5
R&D Webinar to be hosted on 17 June 2025
Ladenburg, Germany, 14 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developi [ … ]
Thu, 24.04.2025
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated
Cohort 8 expected to start soon
Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started
Amendment of contract with [ … ]
